科美诊断(688468) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was CNY 120,882,732.99, representing a year-on-year increase of 0.55%[5] - The net profit attributable to shareholders for the same period was CNY 39,107,317.86, reflecting a growth of 2.54% compared to the previous year[5] - Total operating revenue for Q1 2022 was CNY 120,882,732.99, a slight increase of 0.55% compared to CNY 120,215,653.37 in Q1 2021[19] - Net profit for Q1 2022 reached CNY 39,107,317.86, representing an increase of 2.54% from CNY 38,138,994.23 in Q1 2021[21] - The net profit for Q1 2022 was a loss of ¥6,052,137.88, compared to a loss of ¥2,823,027.53 in Q1 2021, representing an increase in loss of 114.0%[31] Cash Flow - The net cash flow from operating activities increased significantly by 47.22%, amounting to CNY 58,921,042.84, due to increased sales collections and reduced procurement expenditures[6][10] - Cash inflow from operating activities for Q1 2022 was CNY 143,862,718.38, an increase of 10.06% compared to CNY 130,244,977.65 in Q1 2021[24] - The net cash flow from operating activities for Q1 2022 was a negative ¥4,825,094.93, compared to a negative ¥1,011,888.80 in Q1 2021[34] - Investment activities resulted in a net cash outflow of ¥152,610,099.14 in Q1 2022, compared to a net outflow of ¥69,212,760.93 in Q1 2021[34] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,470,694,840.01, showing a growth of 2.78% from the end of the previous year[6] - Total assets as of Q1 2022 amounted to CNY 1,470,694,840.01, an increase from CNY 1,430,906,695.48 in the previous year[17] - Total liabilities for Q1 2022 were CNY 149,390,178.81, a decrease from CNY 152,233,971.04 in Q1 2021[17] - Total liabilities decreased to CNY 29,828,540.71 from CNY 47,669,901.28 year-over-year[29] Research and Development - Research and development expenses totaled CNY 18,502,792.33, accounting for 15.31% of operating revenue, which is an increase of 3.06 percentage points year-on-year[6] - Research and development expenses for Q1 2022 were CNY 18,502,792.33, an increase of 25.5% compared to CNY 14,728,188.25 in Q1 2021[20] - Research and development expenses increased to ¥10,877,795.20 in Q1 2022, up 38.0% from ¥7,879,358.05 in Q1 2021[30] Shareholder Information - The company reported a total of 7,961 common shareholders at the end of the reporting period[10] - The company’s major shareholders include entities with significant stakes, such as Ningbo Yingweili and Ningbo Keboao, with ownership percentages of 79.15% and 5.40% respectively[13] - The company has established a relationship with major shareholders, including a 100% ownership by China Ping An Insurance Group in Ping An Real Estate, which directly holds 70.53% of Ping An Ankang[13] Equity and Earnings - The total equity attributable to shareholders increased by 3.33% to CNY 1,321,304,661.20 compared to the end of the previous year[6] - The basic and diluted earnings per share were both CNY 0.10, down by 9.09% year-on-year[5] - Earnings per share for Q1 2022 were CNY 0.10, down from CNY 0.11 in Q1 2021[21] Inventory and Receivables - Accounts receivable decreased to ¥33,074,579.41 from ¥35,127,292.63, showing a decline of about 5.9%[15] - Inventory levels were reported at ¥116,586,862.72, down from ¥122,362,493.25, indicating a decrease of approximately 4.7%[15] - The company’s inventory as of March 31, 2022, was CNY 32,142,005.62, a slight decrease from CNY 33,822,531.63 in the previous year[27]